Comera SPAC Presentation Deck
SQore Platform Leading to Revenue-Generating,
High-Value Partnerships, with Additional Expected this Year
Selective focus on high-value collaborations with
near-term milestone value
●
●
Partnering Strategy
●
Late-stage clinical programs and/or commercialized
assets
Programs with significant commercial potential
High patient quality-of-life impact with availability of
self-injectable formulation
Emphasis on long-term value creation (royalties,
milestone payments) if collaboration successful
Selective focus on pharma partners having
significant strategic value to Comera
Broad mAb asset portfolio amenable to SQ formulation
with SQore™
Potential interest in licensing and acquiring Comera's
internal assets at downstream stages of development
Partnership #1
●
●
Partnership #2
●
●
●
Current Partnerships
)<
Comera
LIFE SCIENCES
Leading US biotechnology company
Three high-priority assets in development
Option to license after further technical evaluation complete
Top 10 global pharma company
Drug commercialized globally, currently the largest biologic drug
by revenue to Company (top two overall)
Option to license after further technical evaluation complete
21View entire presentation